131 related articles for article (PubMed ID: 16942020)
1. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
3. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
Dessalew N; Bharatam PV
Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
[TBL] [Abstract][Full Text] [Related]
5. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
[TBL] [Abstract][Full Text] [Related]
6. Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.
Jiang Y; Zou J; Gui C
J Mol Model; 2005 Nov; 11(6):509-15. PubMed ID: 15928920
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
8. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.
Duca JS
Future Med Chem; 2009 Nov; 1(8):1453-66. PubMed ID: 21426059
[TBL] [Abstract][Full Text] [Related]
9. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Griffin RJ; Henderson A; Curtin NJ; Echalier A; Endicott JA; Hardcastle IR; Newell DR; Noble ME; Wang LZ; Golding BT
J Am Chem Soc; 2006 May; 128(18):6012-3. PubMed ID: 16669651
[TBL] [Abstract][Full Text] [Related]
10. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
11. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.
Kawanishi N; Sugimoto T; Shibata J; Nakamura K; Masutani K; Ikuta M; Hirai H
Bioorg Med Chem Lett; 2006 Oct; 16(19):5122-6. PubMed ID: 16876403
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping.
Richardson CM; Nunns CL; Williamson DS; Parratt MJ; Dokurno P; Howes R; Borgognoni J; Drysdale MJ; Finch H; Hubbard RE; Jackson PS; Kierstan P; Lentzen G; Moore JD; Murray JB; Simmonite H; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2007 Jul; 17(14):3880-5. PubMed ID: 17570665
[TBL] [Abstract][Full Text] [Related]
13. Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency.
Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ; Parikh MD
Bioorg Med Chem Lett; 2009 Aug; 19(16):4882-4. PubMed ID: 19616942
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates.
Wong C; Griffin RJ; Hardcastle IR; Northen JS; Wang LZ; Golding BT
Org Biomol Chem; 2010 May; 8(10):2457-64. PubMed ID: 20448906
[TBL] [Abstract][Full Text] [Related]
15. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
Cho YS; Borland M; Brain C; Chen CH; Cheng H; Chopra R; Chung K; Groarke J; He G; Hou Y; Kim S; Kovats S; Lu Y; O'Reilly M; Shen J; Smith T; Trakshel G; Vögtle M; Xu M; Xu M; Sung MJ
J Med Chem; 2010 Nov; 53(22):7938-57. PubMed ID: 21038853
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin.
Aubry C; Wilson AJ; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Org Biomol Chem; 2006 Mar; 4(5):787-801. PubMed ID: 16493461
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
[TBL] [Abstract][Full Text] [Related]
18. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
19. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity.
Echalier A; Cot E; Camasses A; Hodimont E; Hoh F; Jay P; Sheinerman F; Krasinska L; Fisher D
Chem Biol; 2012 Aug; 19(8):1028-40. PubMed ID: 22921070
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.
Andrews MJ; McInnes C; Kontopidis G; Innes L; Cowan A; Plater A; Fischer PM
Org Biomol Chem; 2004 Oct; 2(19):2735-41. PubMed ID: 15455144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]